StockNews.AI
GDRX
StockNews.AI
173 days

GoodRx Reports Fourth Quarter and Full Year 2024 Results

1. GoodRx reported Q4 2024 revenue of $198.6 million, net income at $6.7 million. 2. Adjusted EBITDA stood at $67.1 million with a 17.5% adjusted net income margin.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive revenue and adjusted EBITDA indicate financial stability and growth potential. Historical examples of similar earnings results have typically boosted stock prices in the healthcare sector, especially for tech-enabled services.

How important is it?

Strong financial performance can significantly influence investor decisions, enhancing GDRX's market perception. Given the competitive landscape in healthcare technology, positive earnings announcements become pivotal for stock valuation.

Why Short Term?

The quarterly results are likely to affect investor sentiment immediately, with potential stock price movements. Over the longer term, sustained profitability will depend on market conditions and ongoing operational performance.

Related Companies

AMGNCVSPFEMRK
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA.

Related News